Literature DB >> 8554019

Clinical assessment of adrenergic tone and responsiveness to beta-blocker therapy in patients with symptomatic ventricular tachycardia and no apparent structural heart disease.

M A Brodsky1, M V Orlov, B J Allen, Y S Orlov, L Wolff, R Winters.   

Abstract

To further define the relation between changing adrenergic tone, beta-blocker therapy, and clinical ventricular tachycardia (VT), we evaluated these factors in 35 patients with VT unrelated to coronary artery disease or ventricular dysfunction. Testing included Holter monitoring (91% had VT), exercise test (69% had VT), Adrenergic responsiveness of VT was graded according to diurnal variation, response to exercise, isoproterenol infusion, and response to beta-blockers. beta-Blockers were effective and well tolerated in this population. There was also a predictable relation between changing adrenergic tone and the arrhythmia response to beta-blocker therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8554019     DOI: 10.1016/s0002-8703(96)90050-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

1.  Adrenergic nervous system influences on the induction of ventricular tachycardia.

Authors:  Oscar A Pellizzón; Juan S Beloscar; Enrique Mariani
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-10       Impact factor: 1.468

2.  Attenuation by ACE inhibitor drugs of alpha-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity.

Authors:  M Kimura; K Umemura; K Kosuge; M Nishimoto; K Ohashi; M Nakashima
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

3.  Cardiac arrhythmias triggered by sudden and dynamic efforts.

Authors:  Emanuel C Furtado; Claudio Gil S Araújo
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-04       Impact factor: 1.468

Review 4.  Pharmacological management of arrhythmias in the elderly.

Authors:  I C Van Gelder; J Brügemann; H J Crijns
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 4.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.